0001628280-26-015997
SEC filingRevenue declined 12.1% YoY due to lower product volume and divestitures, while gross margin contracted 340 bps.
3D Systems Corporation provides comprehensive 3D printing and digital manufacturing solutions, including printers for plastics and metals, materials, software, and services such as maintenance, advanced manufacturing, and applications engineering. The company markets its products globally through subsidiaries in the Americas, EMEA, and APAC.
The company operates in two key verticals: Healthcare Solutions and Industrial Solutions. Healthcare Solutions encompasses dental, medical devices, personalized health services, and regenerative medicine, with a focus on patient-specific implants, surgical guides, anatomical models, clear aligners, and dentures. Industrial Solutions covers aerospace, defense, transportation, and general manufacturing, targeting high-volume production in automotive and consumer markets as well as mission-critical components for high-reliability industries.
3D Systems offers a broad range of printing technologies, including Stereolithography (SLA), Selective Laser Sintering, Direct Metal Printing, MultiJet Printing, polymer extrusion, and bioprinting. The company provides a wide array of proprietary materials (plastic, nylon, metal, composite, elastomeric, wax, dental, biocompatible) and software solutions like 3D Sprint for polymer workflows and 3DConnect for remote monitoring. The 3DXpert software is sold through a relationship with Hubb Ventures following its divestiture in 2025.
The company utilizes a direct sales force, channel partners, and distributors globally. Customer innovation centers and advanced manufacturing facilities support application development. In 2025, two customers in the Healthcare segment accounted for 12.2% and 11.4% of revenue, and one of those customers also represented 16.0% and 15.0% in 2024 and 2023, respectively.
Competitors include other suppliers of 3D printers, materials, software, and healthcare solutions, as well as providers of conventional manufacturing technologies. The company differentiates through its integrated ecosystem of hardware, materials, software, and application engineering, supported by advanced manufacturing operations and a global services team.
The company's strategy centers on accelerating additive manufacturing adoption by partnering with customers to scale from prototyping to production. Key elements include a strong application focus in Healthcare and Industrial verticals, an Applications Innovation Group, and a full range of hardware and materials. The approach aims to drive recurring revenue through consumables, software, and services.
As of December 31, 2025, 3D Systems employed 1,418 full-time and part-time individuals, a decrease from 1,833 in 2024. Approximately 40% of employees are located outside the US, with geographic distribution of 60% in Americas, 34% in EMEA, and 6% in APAC. The company emphasizes talent development, engagement, and safety through various programs.
For the year ended December 31, 2025, 3D Systems reported total revenue of $386.9 million, a decrease of $53.2 million (12.1%) compared to $440.1 million in 2024. The decline was primarily driven by a $55.8 million drop in product revenue, attributed to lower materials volume in the dental, service bureaus, and jewelry markets, as well as the impact of divestitures. Service revenue increased modestly by $2.6 million, supported by volume growth and favorable foreign currency translation, partially offset by divestiture impacts. The prior year service revenue was also negatively affected by an $8.7 million cumulative catch-up adjustment under a collaboration arrangement.
Gross profit decreased $33.1 million (20.2%) to $131.0 million, with gross margin contracting 340 basis points to 33.9% from 37.3%. The margin compression was primarily due to divestitures and lower sales volumes. Cost of sales declined $20.1 million to $255.9 million, reflecting lower printer and material sales volume.
SG&A expenses fell $48.8 million (23.2%) to $161.3 million, driven by lower compensation and benefits ($21.3 million), reduced third-party service and consulting costs ($19.0 million), and lower intangible amortization ($10.2 million), partially offset by $4.7 million in restructuring severance. R&D expenses decreased $21.4 million (24.8%) to $65.0 million, primarily from lower compensation and improved operating efficiency from restructuring.
Asset impairment charges were $0.8 million in 2025 (a right-of-use asset impairment) versus $145.0 million in 2024, which included a $101.4 million goodwill impairment in Healthcare Solutions and a $42.3 million impairment of long-lived assets in core operations.
Non-operating income totaled $145.7 million, up from $27.4 million, driven by a $139.6 million gain on disposition from the Geomagic and 3DXpert/Oqton divestitures. Interest expense increased $2.6 million due to the new 2030 Notes. Income tax expense rose to $14.9 million from $2.2 million, impacted by the Geomagic gain and foreign return-to-provision adjustments.
Healthcare Solutions revenue decreased $10.1 million (5.3%) to $179.6 million, driven by a $22.4 million decline in product revenue from lower dental material sales to a key customer, partially offset by a $12.3 million increase in services revenue from higher personalized healthcare solutions and parts manufacturing. Segment gross profit fell $1.7 million (2.3%) to $71.8 million, with lower volumes partially offset by favorable price/mix.
Industrial Solutions revenue declined $43.1 million (17.2%) to $207.3 million, reflecting a $33.3 million decrease in printer and materials revenue due to reduced volumes in service bureaus and jewelry markets and divestiture impacts, partially offset by growth in aerospace and defense. Service revenue fell $9.8 million due to divestitures. Segment gross profit dropped $31.4 million (34.7%) to $59.2 million, driven by divestitures, unfavorable price/mix, and lower volumes.
Management highlighted the 2025 Restructuring Plan, authorized in March 2025, which includes streamlining infrastructure and business processes while maintaining core R&D investment. An incremental cost reduction initiative focused on labor force reductions was announced in May 2025. The company does not expect significant additional restructuring charges in 2026 related to this plan.
Liquidity is supported by $95.6 million in cash and equivalents at year-end, though operating cash flow was negative $87.8 million. The company issued $92.0 million in 5.875% convertible senior secured notes due 2030, using proceeds and cash to repurchase $179.7 million of its 2026 Notes. A financial covenant requires maintaining at least $20.0 million in qualified cash, with which the company was compliant. Management expects cash flow from operations, cash equivalents, and other liquidity sources to be sufficient for the next twelve months, but longer-term needs depend on profitability and working capital management.
As of December 31, 2025, the Company held $95.6 million in cash and cash equivalents, down from $171.3 million at year-end 2024. Total debt (carrying value) was $90.3 million, consisting of $3.9 million of 0% convertible notes due 2026 and $86.4 million of 5.875% convertible senior secured notes due 2030. Shareholders' equity was $240.4 million, up from $176.2 million, driven by net income and the conversion of debt to equity. Inventory increased to $127.5 million from $118.5 million.
Remaining performance obligations (RPO) as of December 31, 2025 were $6.5 million, with approximately 90% expected to be recognized within the next two years. The Company also has operating lease liabilities of $57.0 million and finance lease liabilities of $11.1 million. No other material purchase commitments were disclosed in the Notes.
During 2025, the Company repurchased 8.0 million shares of common stock for $14.96 million. No dividends were paid or declared. The Company issued $92.0 million of 5.875% convertible notes due 2030 and used the proceeds, along with $78.0 million of cash, to repurchase $179.7 million of its 0% convertible notes due 2026. Additionally, $30.8 million of the 2026 notes were exchanged for 16.6 million shares of common stock. Capital expenditures were $9.9 million, or 2.6% of total revenue.
The Notes do not provide segment-level revenue or operating income. Revenue by geographic region was: Americas $224.5M, EMEA $135.8M, and APAC $26.6M. The United States contributed $221.0M and Germany $59.3M. Two customers in the Healthcare Solutions segment represented 12.2% and 11.4% of total revenue, respectively.
The filing highlights persistent macroeconomic headwinds including elevated interest rates, uneven inflation, and geopolitical tensions that could tighten customer financing and disrupt supply chains. Trade policy changes and tariff risks are explicitly noted as potential amplifiers of operational costs.
Customer concentration is a key concern: two Healthcare Solutions clients account for 12.2% and 11.4% of revenue, creating concentrated credit risk. The company carries $92.0M in 2030 convertible notes and $3.9M in 2026 notes, with financial covenants requiring $20M minimum cash and $75M in receivables/inventory. Past non-compliance with filing deadlines (2023 10-K, Q1 2024 10-Q) triggered defaults that were cured but underscore liquidity vulnerability. Goodwill impairment charges of $302.8M (2023) and $145.0M (2024) signal ongoing asset valuation risk.
Two material weaknesses in internal control over financial reporting remain unremediated as of December 31, 2025, related to revenue recognition (standalone selling price and transaction price allocation) and market-based stock compensation accounting. Remediation is targeted for fiscal 2026 but not assured. The SEC has been conducting a formal investigation since April 2022, adding to compliance costs and management distraction.
The company faces extensive regulatory exposure: FDA oversight for medical devices, ITAR/EAR export controls (prior violations settled in 2023), FCPA/anti-corruption laws, and environmental regulations (TSCA, REACH, WEEE, RoHS). A BIS administrative subpoena and voluntary disclosures for export violations between 2012-2017 were settled in 2023; the DDTC closed the settlement in February 2026 after all terms were completed.
Dependence on single or limited suppliers for lasers, materials, and jetting components creates vulnerability to disruptions. Rapid technological change and customer needs require continuous R&D investment; regenerative medicine efforts face technical and market risks with no guarantee of commercialization. Cybersecurity threats are ongoing but have not yet materially affected operations.
Past and future acquisitions/divestitures carry integration risks, potential goodwill impairment, and management distraction. The company's ability to attract and retain senior management and key technical talent is challenged by competition from larger, better-resourced firms.
The provided document excerpt does not include the actual cash flow statement figures. It only references the location of the cash flow statements on page F-10. Therefore, no analysis can be performed.